Prior Authorization Legislation Takes Center Stage at Joint Hearing on Health Care Affordability
A joint hearing held on Jan. 22 by the U.S. House of Representatives Energy & Commerce Subcommittee on Health and the Ways and Means Committee hosted...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
Payer Update for Blue Cross Blue Shield New Jersey
TELCOR has identified ongoing processing challenges with BCBS New Jersey that laboratories should be aware of. When claims require medical records,...
Payer Update for BCBS Nebraska
TELCOR has identified a recent process change with BCBSNebraska impacting payment timelines. As of November 1, 2025, BCBSNE adjustedits payment...